A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
NCT01943838
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm Malignant
Interventions
DRUG:
SAR245408
Sponsor
Sanofi